BridgeBio Pharma (BBIO) said Tuesday that the European Commission has granted marketing authorization for acoramidis, under the brand name Beyonttra, to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy.
BridgeBio said German pharmaceutical company Bayer will launch acoramidis in H1 of 2025 in the European Union.
BridgeBio also said that based on its licensing agreement with Bayer, it expects to receive a $75 million milestone payment as well as royalties in a tiered structure on sales of acoramidis in the EU.
Acoramidis has already been approved by the US Food and Drug Administration under the brand Attruby.
Price: 31.80, Change: +0.04, Percent Change: +0.13
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。